CANbridge Pharmaceuticals Doses First Patient in CAN108 Biliary Atresia Study
China-based rare disease specialist CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that the first patient has...
Sandoz Launches Pyzchiva Biosimilar of J&J’s Stelara in US
Switzerland-based Sandoz (SWX: SDZ) announced the launch of Pyzchiva, a biosimilar version of Johnson &...
CDE Includes Chiral Tech’s Cerdelga Generic in Rare Disease Care Plan
China’s Center for Drug Evaluation (CDE) announced the inclusion of Beijing Chiral Tech’s generic version...
Medtronic’s BrainSense Adaptive DBS Wins FDA Approval for Parkinson’s Treatment
US-Irish medical device giant Medtronic (NYSE: MDT) announced that the US Food and Drug Administration...
SMPA Suspends Indobufen Procurement After Patent Infringement Verdict
Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) announced the suspension of procurement for indobufen, manufactured by...
Xellsmart’s iPSC Therapy XS-228 Receives FDA Approval for ALS Study
Suzhou-based stem-cell startup Xellsmart announced that the U.S. FDA has approved its regulatory study of...
Huadong Medicine’s HDM1005 Receives NMPA Approval for OSA Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its HDM1005, a long-acting GLP-1/GIP receptor...
Pfizer’s Hympavzi (Marstacimab) Launched in China’s Boao Lecheng Pilot Zone for Hemophilia
Pfizer Inc. (NYSE: PFE) announced the implementation of its hemophilia therapy Hympavzi (marstacimab) in China’s...
Summit Therapeutics and Pfizer Collaborate on Ivonescimab-ADC Combo for Solid Tumors
Summit Therapeutics Inc. (NASDAQ: SMMT), the U.S. partner of China-based Akeso Inc. (HKG: 9926) for...
Dizal Pharma’s 2024 Revenues Surge 295% to RMB360M, Loss Narrows by RMB251M
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial preview, showing annual revenues...
Bristol-Myers Squibb’s Opdivo-Yervoy Combo Nears FDA Approval for MSI-H Colorectal Cancer
Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the U.S. FDA has accepted its filing for...
CanSino Biologics Receives NMPA Approval for DTcP Hib MCV4 Combined Vaccine
China-based vaccine specialist CanSino Biologics Inc. (HKG: 6185) announced that its absorbed diphtheria, tetanus, acellular...
MGI Tech Partners with Oncoclínicas&Co to Advance Precision Medicine in Brazil
China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has partnered with OC Medicina...
Boehringer Ingelheim’s Nerandomilast Receives NMPA Review for IPF Treatment
Boehringer Ingelheim announced that its investigational drug nerandomilast has been accepted for review by the...
QYuns Therapeutics’ QX002N Meets Primary Endpoint in AS Phase III Study
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that its Phase III study of...
Takeda’s Takhzyro Receives EMA Approval for New Administration Form in HAE Patients
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) announced that the European Medicines Agency (EMA) has approved...
National Allied Procurement Office Allows VBP Winners to Adjust MAH and Manufacturing Details
The National Allied Procurement Office has issued a notification clarifying rules for China’s Volume-Based Procurement...
Ipsen Posts 8.7% Revenue Growth in 2024, Driven by Rare Diseases and Oncology
French biopharma firm Ipsen (EPA: IPN, OTCMKTS: IPSEY) reported an 8.7% year-on-year (YOY) increase in...
Meyer FSMP Hong Kong Secures NMPA Approval for First FSMP in Greater China
Hong Kong-based Meyer FSMP Hong Kong Limited, an oncology-focused foods for special medical purpose (FSMP)...
Pfizer Halts Global Development of Hemophilia B Gene Therapy Beqvez Amid Limited Demand
Pfizer Inc. (NYSE: PFE) has terminated the development and commercialization of Beqvez (fidanacogene elaparvovec), its...